Tylenol's crisis manager Lawrence Foster dies at 88

Share this article:

The man behind Johnson & Johnson's legend-making response to the 1982 Tylenol poisoning scare has died. The New York Times reports that Lawrence Foster, a former journalist and head of J&J's PR department, died at the age of 88. Foster had cancer and heart failure.

Under Foster's direction, the company halted all Tylenol advertising and pulled more than 30 million bottles off the shelves. Seven died after consuming capsules that had been tampered with after production and cyanide was added to capsules already on store shelves. According to a University of Florida project about the crisis, Tylenol's hold on the market fell from 37% to 7%.

Foster advised Johnson & Johnson's then-chair James Burke to be the face of the reputation campaign that is now a touchstone of crisis management and led to the brand rising to a 30% market share after the product returned to stores. Foster's strategy was to provide a human element and ownership of the crisis, without polish. Then-chair of McNeil, David Collins, tells the Times Foster's direction was “tell them what we know, and we're not going to tell them what we don't know. We'll tell them we don't know, and we'll get back to them when we do know.”

The company's multi-prong strategy for regaining consumer confidence included tamper-resistant packaging (and replacing capsules with caplets), consumer discounts, and sending sales reps into the field to talk to doctors about the product's integrity.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.